XNCR Xencor Inc

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
• • New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
• • Strategic shift: Prioritization of T cell-engaging bispecific antibody programs in oncology, expanding XmAb 2+1 bispecific format applications in solid tumors
• • Quantitative metric: Phase 1 XmAb819 RCC study enrolled 69 patients, 25% partial response rate, 70% disease control rate; XmAb942 Phase 2b initiated in ulcerative colitis
• • Noteworthy fact: Collaboration revenues include $70.1M royalties from Alexion’s Ultomiris and $10.2M from Incyte’s Monjuvi in 2025, highlighting growing partner-generated income

Risk Factors

• • Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
• • Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
• • Supply chain vulnerability relying on third-party manufacturers, contract research organizations, and collaborators for manufacturing and clinical execution
• • Competitive risk from other biotech/pharma firms with new products and technologies impacting market position and stock volatility
• • Financial risk of significant net loss $91.9M in 2025, accumulated deficit $796.0M, requiring additional financing beyond $610.8M cash reserves to fund operations through 2028

Management Discussion & Analysis

• • Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
• • Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
• • Best segment Royalties $80.3M in 2025, up $12.8M YoY; worst segment License revenues $0 in 2025 vs $8.5M in 2024
• • No specific cash flow, buybacks, dividends, or capex data disclosed in the provided section
• • Management emphasizes disciplined portfolio management and clinical data-driven strategy; no explicit forward guidance stated

What are the latest XNCR SEC filings in 2026?

Xencor Inc (XNCR) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did XNCR file its most recent 10-K annual report?

Xencor Inc (XNCR) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view XNCR 10-Q quarterly reports?

Xencor Inc (XNCR)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every XNCR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has XNCR filed recently?

Xencor Inc (XNCR)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find XNCR insider trading activity (Form 4)?

SignalX aggregates every XNCR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does XNCR file with the SEC?

Xencor Inc (XNCR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new XNCR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Xencor Inc (XNCR).

What is XNCR's SEC CIK number?

Xencor Inc (XNCR)'s SEC CIK (Central Index Key) number is 1326732. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1326732 to look up all XNCR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find XNCR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Xencor Inc (XNCR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.